Technology

Targeting Cancer on Two Fronts

IMPACT-2X is a proprietary hydroxylase-releasable masking technology used to generate tumor-specific conditionally activated-small molecule drug conjugates (CA-SMDCs) for the treatment of a broad range of solid tumors.

MaGroup 20
Play Video about MaGroup

Groundbreaking Class of Therapeutics

Emerging first-in-class therapeutics combine the benefits of small molecules with the unique metabolic conditions of cancer and the tumor immune microenvironment to localize treatment to the tumor while limiting activity in normal tissue.

Innovative Targeting Approach

Exploits tumor-associated hydroxylases that are over-expressed to a high frequency in many solid tumors while co-targeting immune-associated hydroxylases in immunosuppressed and immunogenically “cold” tumors.

Game-Changing and Disruptive Potential

Our innovative CA-SMDC platform of drug candidates have the potential to challenge the limitations of current drug conjugate and conditionally activated therapeutics while overcoming resistance to chemotherapy and immunotherapy.

Targeted to Cure

The MaveriX Technology approach is independent of cancer stage and facilitates the targeting of both early stage and more aggressive later-stage metastatic cancers with clear clinical unmet need.

IMPACT-2X a Holistic Tumor Targeting Strategy

The tumor immune microenvironment plays a significant role in tumor growth, metastasis, and therapeutic resistance involving metabolic crosstalk between immune cells and cancer cells. Cancer metabolism and immune escape are major hallmarks of cancer resulting in conditional metabolic reprogramming of tumors, but not normal tissues. IMPACT-2X represents a unique targeting strategy that facilitates direct targeting of tumors while co-targeting immunosuppressive cell subsets in immunogenically cold tumors, which is currently a major therapeutic challenge to immunotherapy. IMPACT-2X represents a holistic approach for the targeted treatment of solid tumors.

IMPACT-2X

Cancer

Targeted oncology
Improved therapeutic index
Overcome resistance in cancer
Precision therapeutics
Monotherapy

Tumor Immune Microenvironment

Targeted immuno-oncology
Improved immune index
Overcome immunosuppression
Stimulate anti-tumor immunity
Combination therapy

CA-SMDC Discovery Paradigm

Artificial Intelligence (AI)-assisted CA-SMDC design combines high throughput and virtual screening (HTS/ HTVS) with AI-Machine Learning algorithms to accelerate CA-SMDC discovery with robust target selectivity.

Mask Group 188@2x

CA-SMDC Therapeutics

CA-SMDCs have been intentionally designed to selectively target tumors, and not healthy normal tissue with the goal of creating safer, more effective cancer therapies. Our CA-SMDC drug candidates are designed based on our deep understanding of hydroxylase biology in cancer and the tumor immune microenvironment. CA-SMDC are stable and inactive until they engage tumor and immune-associated hydroxylases that trigger CA-SMDC fragmentation to deliver an active drug or payload selectively to the tumor.

Our unique discovery paradigm enables the modular design of CA-SMDCs, which combine our proprietary target-selective PROXACT – molecular mask with an integrated hydroxylase cleavable linker technology conjugated to a chosen drug or payload.

Group 27 (1)

CA-SMDC Target Tracking

  • Stable and "inactive" CA-SMDC rapidly penetrates solid tumors.
  • Tracks to intracellular hydroxylase target.

CA-SMDC Target Engagement

  • PROXACT molecular mask binds specifically within target hydroxylase.
  • Orientates CA-SMDC for efficient payload release.

CA-SMDC Fragmentation

  • Efficient target activation results in linker fragmentation with demasking.
  • Linker fragmentation releases "active" payload selectively in the tumor.

Our deep experience in hydroxylase biology and drug-conjugate chemistry has led to the generation of a multi-target, multi-asset platform of CA-SMDC drug candidates for the treatment of a broad range of early and late-stage solid tumor cancers.

Our goal is to replace standard-of-care chemotherapy for the treatment of early-stage solid tumors and compete with other drug-conjugate therapeutics, including antibody and peptide drug conjugates in the treatment of late-stage metastatic cancer. CA-SMDCs are designed for monotherapy activity in the clinic, but we foresee a significant opportunity for combination therapy, particularly in solid tumors that are immunogenically cold and resistant to immunotherapy.

CA-SMDC Precision Therapeutics

MaveriX combines transcriptomic and proteomic co-expression analysis of oncogenic and immunogenic markers in cancer versus normal tissue to identify novel hydroxylase targets that drive tumor growth, metastasis, and immune suppression. Our translational approach includes creating novel assays as companions to our development candidates to identify patients that will gain therapeutic benefit from treatment.
Group 1684